Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis

The addition of bevacizumab to chemotherapy has demonstrated efficacy as a first-line treatment for non-small cell lung cancer (NSCLC). Whether this combination is effective as a salvage treatment for patients with NSCLC remains unclear. The present retrospective study was designed to compare the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Binbin, Zhou, Xiaojuan, Liu, Yongmei, Li, Qian, Xiang, Mengmeng, Zou, Bingwen, Peng, Feng, Huang, Meijuan, Gong, Youling, Zhu, Jiang, Wang, Yongsheng, Ren, Li, Xu, Yong, Zhang, Yan, Li, Yanying, Yu, Min, Xue, Jianxin, Deng, Lei, Wang, Jin, Ding, Zhenyu, Lu, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844063/
https://www.ncbi.nlm.nih.gov/pubmed/29556304
http://dx.doi.org/10.3892/ol.2018.8064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844063/
https://www.ncbi.nlm.nih.gov/pubmed/29556304
http://dx.doi.org/10.3892/ol.2018.8064

Ejemplares similares